INTRODUCTION
The mammalian lung is stabilized by a specialized material, the pulmonary surfactant, which reduces the surface tension at the air/liquid interface of the alveoli (Goerke, 1974) . Pulmonary surfactant contains a number of lipids, including disaturated and unsaturated phosphatidylcholine (PC), phosphatidylglycerol (PG) and phosphatidylethanolamine (PE). Natural surfactant also contains two major apoproteins with nominal molecular masses 35 and 11 kDa. Previous investigations on the role of these proteins in surfactant function have largely emphasized the 35 kDa moiety (King, 1984a (King, ,b, 1985 Hawgood et al., 1985) . Nevertheless, it has become apparent that protein-poor lipid extracts of pulmonary surfactant retain some of the physical and biological properties attributed to natural surfactant (Notter, 1984; Possmayer et al., 1984; Berggren et al., 1985) . Treatment of prematurely delivered infants with a heat-sterilized emulsion of 'lipid-extract surfactant' (defined below) resulted in a marked improvement in lung function and a reduction in neonatal mortality (Enhorning et al., 1985) . The present investigation reports that the lipid-extract surfactant used in this trial lacked the 35 kDa apoprotein but contained the 6 kDa apoprotein. Such extracts retain their surfactant activity when assayed on a pulsating-bubble surfactometer. The results also demonstrate that active preparations can be reconstituted by combining the 6 kDa apoprotein with the appropriate lipids.
MATERIALS AND METHODS Preparation of natural surfactant and surfactant components
Bovine lung surfactant and lipid extracts were prepared from freshly slaughtered cattle by a slight modification of methods described in previous publications from this laboratory (Yu et al., 1983; . 'Natural surfactant' refers to the white material collected at the interface after gradient centrifugation over 0.75 M-sucrose/0.9% NaCl and redispersed in saline (0.9 o NaCl) alone. 'Lipid-extract surfactant' refers to the phospholipid fraction precipitated from chloroform with cold acetone.
Samples of lipid-extract surfactant containing 300 mg of lipid in chloroform were applied to a column containing 5 g of activated silicic acid (200-400 mesh, Bio-Sil A; Bio-Rad). Fractions (50 ml each) were quantitatively analysed by t.l.c. with chloroform/ethanol/ triethylamine/water (30:34:35:8, by vol.). Protein was determined by a modification of the Lowry method and phospholipid phosphorus by the Rouser method as previously described (Yu et al., 1983) .
Reconstitution of surfactant samples
The fractions from the silicic acid column in chloroform/methanol (9: 1, v/v) were mixed as desired, dried underN2 anddispersedin0.900 NaCl/ 1.0 mM-CaCl2 to yield 1 % lipid and 0.01 % protein (w/v) . The suspensions were dispersed with a wrist-action shaker for 1 h at room temperature and incubated at 37°C for 1-2 h. Where indicated, protein fractions were treated overnight at 37°C with trypsin or Pronase (Sigma Chemical Co., St. Louis, MO, U.S.A.) at 2 mg/ml in 50 mM-Hepes/ 1.0 mMCaCl2/0.900 NaCl/0.02% NaN3, pH 7.5, before reconstitution. Surface-tension determinations Surfactant activities were measured with a pulsatingbubble surfactometer (Enhorning, 1977; Yu et al., 1983; Possmayer et al., 1984) . A bubble communicating with ambient air is created by withdrawing a small quantity of surfactant suspension from the test chamber (Fig. 1) . The bubble is pulsated between a maximum radius (rmax.) of 0.55 mm and a minimum radius (rmin.) of 0.40 mm at 37 'C. Surface tensions are calculated from the pressure tracings after 1 min pulsation using the Laplace equation . Other methods SDS/polyacrylamide-gel electrophoresis was conducted as described by Laemmli (1970 , 1981) . Immunodiffusion studies were conducted by the method of Ouchterlony (1953) .
RESULTS AND DISCUSSION
Isolation of surfactant components Natural surfactant prepared from bovine lung has a protein pattern (Fig. 2 , lane 2) similar to that previously reported (Yu et al., 1983) . Repeated extraction of natural surfactant with chloroform/methanol by the method of Bligh & Dyer (1959) (King & MacBeth, 1981; Hawgood et al., 1985) or without (Morley et al., 1979; Bangham et al., 1979; Obladen et al., 1979; Yu et al., 1984) 35 kDa apoprotein. Consequently it was deemed important to obtain additional evidence implicating the 6 kDa apoprotein present in F1 and Fl1 in surfactant activity. In agreement with previous results (Metcalfe et al., 1980; Possmayer et al., 1984) , the surface-tension-reducing ability of lipid-extract surfactant is resistant to trypsin but susceptible to Pronase (Table 2) . For reconstitution studies, the protein-containing fraction was treated with proteolytic enzymes before lipid addition. because of the extensive streaking, samples treated with either proteinase still overlapped with controls on SDS/polyacrylamide gels. Consequently, it was not possible to demonstrate directly that degradation had occurred. Therefore it is conceivable that the effects noted with Pronase could be due to the physical presence of exogenous protein in the manner previously reported for a 110 kDa serum protein by Ikegami et al. (1984) . Surfactant apoproteins apparently function by promoting the formation of a surface-active monolayer from bilayer lipids. The precise mechanism(s) by which apoproteins affect lipid structure and/or mobility is not understood. Possmayer et al. (1984) recently proposed that the surface-active monolayer might be formed via two processes termed the 'protein-facilitated' and the 'protein-mediated' mechanisms. Both processes promote the adsorption and spreading of DPPC to yield an equilibrium surface tension of 27 mN (27 dynes)/m. The protein-facilitated process requires only low concentrations (10-15,ug/ml) of lipid, but does require native undenatured 35 kDa apoprotein. This process is sensitive to boiling and exposure to organic solvents, trypsin and 5 mM-EDTA. The same treatments do not affect the protein-mediated process. This latter process requires relatively high concentrations of lipid (2500-5000,g/ml) and protein. The results presented here clearly implicate the 6 kDa apoprotein in the latter process.
Although the suggestion that pulmonary surfactant can form a monolayer of DPPC by two processes requires further clarification, this proposal serves to clarify many apparently conflicting observations (Notter, 1984; Possmayer et al., 1984) . The reason why two apparently separate processes requiring different proteins have evolved to stabilize the mammalian lung is not clear. A number of independent investigations, including several human trials, demonstrate that lipid-extract surfactants possess biological activity (Fujiwara, 1984; Notter, 1984; Possmayer et al., 1984; Enhorning et al., 1985) . The results presented in the present paper strongly suggest that this activity is related to the 6 kDa apoprotein. Whitsett and his co-workers (J. A. Whitsett, B. L. Ohning, J. Ross, T. Meuth, B. A. Weaver, D. L. Holm, Fig. 4 . Characterization of 35 kDa and 6 kDa surfactant apoproteins by immunodiffusion 1, Lung surfactant (0.25 mg/ml); 2, 35 kDa protein (0.1 mg/ml); 3, bovine serum (undiluted); 4, 6 kDa protein (O.1 mg/ml); 5, 6 kDa protein (0.5 mg/ml); 6, 6 kDa protein (1 mg/ml); 7, 6 kDa protein (0.5 mg/ml); 8, bovine serum (undiluted); 9, 35 kDa protein (1 mg/ml); 10, 35 kDa protein (0.5 mg/ml). Antisera were raised in rabbits. 35 kDa apoprotein was eluted from SDS/polyacrylamide gels (Hunkapiller et al., 1983) . Lipid extract was used as the source of 6 kDa aproprotein for raising antiserum. Delipidated 6 kDa apoprotein was used as antigen. Approx. 20,u of undiluted antisera were applied to the centre wells and 10 ,u1 of potential antigen were used in the peripheral wells. Abbreviations used: anti-35k and anti-6k, anti-(35 kDa protein) and anti-(6 kDa protein) antisera.
D. L. Shapiro & R. H. Notter, unpublished work) have recently shown that the organic-solvent extracts of calf lung surfactant used to prepare surfactant for the clinical trials conducted by Kwong et al. (1985) and Shapiro et al. (1985) contain only 5-6 kDa apoprotein, yet have the full biophysical activity of whole lung surfactant. However, the relative importance ofthe protein-facilitated (35 kDa apoprotein) process and the protein-mediated (6 kDa apoprotein) process in the lung under normal conditions must still be determined.
Possibly owing to its hydrophobic nature, the 6 kDa apoprotein has been studied less extensively than its 35 kDa counterpart. The isolation of a low-molecularmass apoprotein was first reported for dog surfactant by King et al. (1973) . This apoprotein was assigned a molecular mass of 10-12 kDa. Although early results (see King, 1 984b) indicated that the major surfactant apoproteins share common epitopes, antisera raised against the 6 kDa and the 35 kDa apoproteins from bovine surfactant exhibit no cross-reactivity (Fig. 4) . Phizackerley et al. (1979) reported that pig lung surfactant contained several hydrophobic proteins. Although further studies are required, N-terminal analysis indicates the 6 kDa apoprotein reported here is more than 90% pure. Suzuki et al. (1982 Suzuki et al. ( , 1984 observed that partially purified protein fractions containing the hydrophobic apoproteins of less than 15 kDa from pig surfactant were more effective in promoting DPPC adsorption than fractions containing the 35 kDa aproprotein.
However, the possibility that the 6 kDa apoprotein described here corresponds to a separate entity cannot be discounted. Fisher and co-workers have reported that rat surfactant contains a 6.2 kDa hydrophobic protein which promotes uptake of surfactant lipids by type II cells in culture (Claypool et al., 1985; Fisher et al., 1985) . Depending on the mode of preparation, various amounts of other proteins can be isolated with surfactant (King, 1984a) , but their relevance to surfactant function is vague. The present studies clearly implicate the 6 kDa apoprotein in the physicochemical and biological properties associated with pulmonary surfactant. Further investigations are required to confirm these observations and to determine the precise mechanism by which surfactant apoproteins influence lipid-lipid interaction and monolayer formation.
Note added in proof (Received 25 February 1986) Since this manuscript was submitted, we have received permission to quote studies by Y. Suzuki. T. Curstedt, G. Grossman, T. Kobayashi, R. Nilsson, K. Nohara & B.
Robertson (personal communication) . Their investigations demonstrated not only that surfactant reconstituted from the low-molecular-mass (15 kDa or less) apoprotein is active with the pulsating-bubble apparatus, but have also demonstrated that these recombinants exhibited biological activity with prematurely delivered rabbits.
